Anti–tumor necrosis factor drugs are expensive, and there are a limited number of choices for IBD treatment, highlighting the need to use every existing agent optimally.
Anti—tumor necrosis factor (TNF) agents, including infliximab and adalimumab, have revolutionized the treatment of inflammatory bowel disease (IBD). However, primary nonresponse (defined as no initial clinical benefit to therapy) and secondary loss of response (defined as a loss of response after an initially favorable outcome) are common, with resulting adverse outcomes. Among infliximab- and adalimumab-treated patients with IBD, primary nonresponse occurs in 10% to 30% of patients, while secondary loss of response occurs in 23% to 46% of patients by 12 months. Anti-TNF drugs are expensive, and there are a limited number of choices for IBD treatment, highlighting the need to use every existing agent optimally. Recently, anti-TNF dosing guided by therapeutic drug monitoring (TDM) has emerged as a potential strategy to optimize treatment and maximize benefit from these drugs, but there has been no formal consensus about TDM-guided anti-TNF dosing.
Recently, a group of 25 IBD experts from the Australian Inflammatory Bowel Disease Consensus Working Group and other international experts published recommendations on TDM in anti-TNF therapy that supported the role of TDM in optimizing treatment with anti-TNF agents for patients with IBD, particularly in situations of treatment failure.
The committee recommends TDM of anti-TNF agents upon treatment failure, following successful treatment induction, and when contemplating a drug holiday. However, the group said there is inconsistent evidence for proactive TDM, and therefore advise that TDM should be performed for patients in stable remission only if results are likely to impact clinical management. The assembly’s statement was published on October 13, 2017, in Alimentary Pharmacology and Therapeutics.
The statement presents an appropriate therapeutic range for infliximab and adalimumab that was delineated to make the guidelines more clinically applicable. The statement also makes the following recommendations:
In order to reach their conclusions, the experts examined scenarios concerning when TDM of anti-TNF agents should be performed, the general approach to patients with symptoms of active disease while receiving anti-TNF therapy, the interpretation of TDM results in patients with confirmed active inflammatory disease who are on anti-TNF therapy, interpreting TDM results among patients in clinical remission who are on anti-TNF therapy, target drug trough levels, anti-drug antibodies, and TDM for other types of biological agents as well as future therapies.
The final recommendations were reached through a consensus process using a modified Delphi technique that used 3 iterations. The panelists agreed on the level of evidence and grade of recommendation according to Australian National Health and Medical Research Council guidelines, and all members of the delegation approved the final draft recommendations prior to submission for publication.
“In conclusion, TDM of anti-TNF agents is an important component of personalized therapy in IBD,” the experts state. “These consensus statements should provide a practical guide to applying TDM of anti-TNF agents in treatment optimization for IBD patients.”
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patients With IBD Experience Nocebo Effect Post Mandatory Switch to Biosimilar
May 11th 2024In Canada, a study on patients with inflammatory bowel disease (IBD) switching to infliximab or adalimumab biosimilars found no change in clinical remission or antidrug antibodies after 24 weeks, but 13% experienced the nocebo effect, leading to one-fifth discontinuing therapy.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.